In this episode of the Psychedelic Spotlight podcast, we spend some time with Timothy Ko who is the CEO of Entheon Biomedical (CSE: ENBI) (OTCQB: ENTBF) (FSE: “1XU1”), a biotechnology company focused on developing psychedelic medicines to treat addiction.
In our conversation with Mr. Ko, we discuss how the company plans to utilize the psychedelic compound DMT to address the global addiction crisis and use genetics to develop more effective personalized treatment regimens for patients.
*To learn more about the company featured in this episode and the work they’re doing, visit their website: https://entheonbiomedical.com
*Get the latest industry news around all things psychedelics by visiting our website, and be sure to subscribe to our newsletter to never miss a thing.
Subscribe to our YouTube channel: https://bit.ly/3prTiCI
Visit our Website: https://psychedelicspotlight.com
Follow us on Instagram: https://instagram.com/psycspotlight
Like us on Facebook: https://facebook.com/PsychedelicSpotlight
Follow us on Twitter: https://twitter.com/PsycSpotlight
*This episode was recorded on May 5, 2021.
#Psychedelics #Stocks #News #Business #DMT # Clinincal #Addiction #Genetics
Have you heard about our new community?
We’re excited to announce Bonfire -
a personal growth community for people who are interested in psychedelics.
Join us for our launch event on July 18th, where we’ll share about the work we’ll be doing together to actualize our personal missions, grow, and heal together.
Psychedelic Spotlight is your reliable source for the latest stories in the emerging psychedelics industry, covering breakthrough discoveries, investor news and cultural reform.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.